Alpharma S.a.s.

Alpharma S.A.S. is a Colombian pharmaceutical company specializing in hemato-oncology, focusing on the commercialization and distribution of specialized medications, including single-dose and high-volume formulations. Established on January 9, 1996, the company has been a pioneer in Colombia, being the first to construct and certify Mixing Centers equipped with cutting-edge technology for the preparation and adjustment of medication dosages. These facilities are certified by INVIMA, ensuring the quality and safety of the prepared medications. (alpharma.com.co)

Headquartered at Avenida Calle 116 No. 70C-12, Bogotá, Colombia, Alpharma S.A.S. operates with a commitment to improving the lives of patients through innovative treatments and services. The company also has an international presence with Alpharma Alliance located in Madrid, Spain, indicating its strategic approach to expanding its reach within Latin America and beyond. (alpharma.com.co)

Alpharma S.A.S. maintains a robust distribution network within Colombia, with its main office situated in Bogotá. The company operates several Mixing Centers, including facilities at Hospital Universitario San Ignacio (HUSI) and Colsubsidio Roma, which are integral to their operations. (alpharma.com.co) These centers are strategically located to serve various regions, ensuring efficient distribution and accessibility of their specialized pharmaceutical products. While specific details about their logistics capabilities and geographic coverage beyond Colombia are not publicly disclosed, the presence of Alpharma Alliance in Madrid suggests a potential for broader distribution within Latin America and Europe.

Alpharma S.A.S. plays a pivotal role in Colombia's pharmaceutical supply chain as a primary wholesaler and distributor, specializing in hemato-oncological medications. The company's operations encompass the importation, commercialization, and distribution of specialized pharmaceutical products, including single-dose and high-volume formulations. Additionally, Alpharma S.A.S. offers pharmaceutical services such as medication adequacy in mixing centers, catering to the specific needs of healthcare providers and patients. (alpharma.com.co)

Alpharma S.A.S. demonstrates a high degree of supplier concentration, primarily sourcing its pharmaceutical products from two Indian suppliers: Venus Remedies Limited and Emcure Pharmaceuticals Limited. Venus Remedies Limited accounts for approximately 73.3% of the total shipments, while Emcure Pharmaceuticals Limited comprises about 26.7%. This sourcing strategy indicates a strategic choice to maintain strong, focused relationships with key suppliers, potentially ensuring consistency in product quality and supply chain reliability.

The shipment data reveals a stable and ongoing relationship with these suppliers, as evidenced by the consistent importation of products over the years. This stability suggests that Alpharma S.A.S. has established reliable partnerships, which are crucial for maintaining the quality and availability of specialized pharmaceutical products in the Colombian market.

Alpharma S.A.S.'s supply chain resilience appears robust, primarily due to its focused sourcing strategy from two key Indian suppliers. The company's importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a diversified product portfolio, which can mitigate risks associated with dependency on a single product line.

However, the reliance on two suppliers may expose Alpharma S.A.S. to potential supply chain disruptions. To enhance resilience, the company could consider diversifying its supplier base and establishing relationships with additional manufacturers. Ensuring that all suppliers comply with international Good Manufacturing Practice (GMP) standards is essential to maintain product quality and regulatory compliance.

Alpharma S.A.S.'s concentrated sourcing strategy positions the company to leverage strong, focused relationships with its key suppliers, potentially ensuring consistency in product quality and supply chain reliability. This approach may also allow for better negotiation terms and streamlined logistics.

For Indian exporters seeking to become alternative suppliers to Alpharma S.A.S., understanding the company's specific product requirements and quality standards is crucial. Demonstrating compliance with international GMP standards and offering competitive pricing could enhance the attractiveness of their products. Additionally, showcasing a proven track record in supplying similar products to other international markets may further strengthen their position.

In Colombia, the National Institute for Food and Drug Surveillance (INVIMA) serves as the primary regulatory authority overseeing the pharmaceutical sector. INVIMA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous evaluation and monitoring processes.

Key legislation governing pharmaceutical imports includes the Health Code and the Decree 4725 of 2005, which outlines the requirements for the importation, registration, and commercialization of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining INVIMA registration, which requires comprehensive documentation, including proof of GMP compliance, product dossiers, and stability data.

Import licensing requirements in Colombia stipulate that all pharmaceutical products must be registered with INVIMA before importation. This process involves submitting detailed product information, including manufacturing processes, quality control measures, and clinical data.

Recognition of GMP certificates from reputable authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S), is essential for facilitating the registration process. Indian exporters holding these certifications can streamline their entry into the Colombian market. Additionally, obtaining wholesale distribution authorization from INVIMA is mandatory for entities involved in the distribution of pharmaceutical products within Colombia.

Pharmaceutical products imported into Colombia must undergo batch testing to ensure compliance with INVIMA's quality standards. Stability studies are required to demonstrate the product's shelf-life and efficacy over time.

Labeling requirements include providing information in Spanish, detailing the product's composition, dosage instructions, storage conditions, and expiration date. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Colombia has implemented several regulatory changes affecting pharmaceutical imports. These include updates to the Health Code and Decree 4725 of 2005, introducing stricter requirements for product registration and importation procedures. The amendments aim to enhance the safety and efficacy of pharmaceutical products available in the Colombian market. Additionally, INVIMA has increased its focus on post-marketing surveillance to monitor the performance of imported pharmaceuticals.

Alpharma S.A.S.'s focus on hemato-oncology is driven by the significant demand for specialized cancer treatments in Colombia and Latin America. The company's importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a comprehensive approach to meeting the diverse needs of healthcare providers and patients.

The market demand for these products is influenced by factors such as the prevalence of hematological malignancies, advancements in treatment protocols, and the need for high-quality, accessible medications. Alpharma S.A.S.'s strategic focus aligns with these market dynamics, positioning the company as a key player in the provision of specialized oncological treatments.

Alpharma S.A.S. employs a strategic sourcing approach, primarily importing finished pharmaceutical formulations from India. This strategy allows the company to offer a diverse product portfolio, catering to various therapeutic needs within the hemato-oncology sector.

India's established reputation for manufacturing high-quality generic pharmaceuticals aligns with Alpharma S.A.S.'s procurement strategy, ensuring access to cost-effective and reliable products. The company's sourcing profile reflects a commitment to maintaining high standards of quality and efficacy in its product offerings.

Alpharma S.A.S. serves the specialized segment of the Colombian pharmaceutical market, focusing on hemato-oncology treatments. The company's product mix positions it to cater to healthcare providers, hospitals, and specialized clinics requiring advanced oncological therapies.

By offering a range of specialized medications and services, Alpharma S.A.S. differentiates itself in the market, addressing the specific needs of patients with hematological malignancies and contributing to the advancement of cancer care in Colombia.

There is a realistic opportunity for new Indian suppliers to enter the Colombian market by aligning with Alpharma S.A.S.'s focus on hemato-oncology. To capitalize on this opportunity, suppliers should ensure compliance with INVIMA's regulatory requirements, including obtaining GMP certifications recognized by Colombian authorities.

Identifying gaps in Alpharma S.A.S.'s current sourcing, such as specific formulations or dosage forms not currently imported, could present avenues for new suppliers to introduce their products. Collaborating with Alpharma S.A.S. to meet these unmet needs could lead to mutually beneficial partnerships.

Indian exporters aiming to supply Alpharma S.A.S. and the Colombian market must obtain GMP certifications from recognized